Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 4:10 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schwannoma Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Vestibular Precision: Physiology & Pathophysiology

NCT04890132
View directory record Official record
Conditions
Vestibular Schwannoma, Inner Ear Disease, Dizziness, Neurofibromatosis 2, Vestibular Disorder
Interventions
VOR precision training
Behavioral
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
8 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 2 Interventional Results available

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

NCT01125046
View directory record Official record
Conditions
Acoustic Schwannoma, Adult Anaplastic Meningioma, Adult Ependymoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Meningeal Hemangiopericytoma, Adult Papillary Meningioma, Neurofibromatosis Type 1, Neurofibromatosis Type 2, Recurrent Adult Brain Tumor
Interventions
bevacizumab
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
5
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Nov 2, 2026, 4:10 PM EST
Terminated Phase 2 Interventional Results available

Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

NCT03095248
View directory record Official record
Conditions
Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma, Glioma
Interventions
Selumetinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Nov 2, 2026, 4:10 PM EST
Terminated Phase 3 Interventional Results available

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

NCT03710564
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Brolucizumab, Aflibercept
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
60
States / cities
Phoenix, Arizona • Beverly Hills, California • Huntington Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

NCT00973739
View directory record Official record
Conditions
Neurofibromatosis 2, Vestibular Schwannoma
Interventions
Lapatinib
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
4 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Nov 2, 2026, 4:10 PM EST
No Longer Available No phase listed Expanded access

Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients

NCT02589912
View directory record Official record
Conditions
Neurofibromatosis Type 2, Severe Profound Sensorineural Hearing Loss
Interventions
Nucleus Profile ABI541 Auditory Brainstem Implant
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
12 Years to 80 Years
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Nov 2, 2026, 4:10 PM EST
Completed Not applicable Interventional Results available

Stereotactic Body Radiotherapy for Spine Tumors

NCT01347307
View directory record Official record
Conditions
Spinal Metastases, Vertebral Metastases, Benign Spinal Tumors, Chordoma, Meningioma, Schwannoma, Neurofibroma, Paragangliomas, Arteriovenous Malformations
Interventions
SBRT for Benign Extradural Spine Tumors, SBRT for Vertebral/Paraspinal Metastases
Radiation
Lead sponsor
Mercy Research
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 1 Interventional

An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors

NCT00030043
View directory record Official record
Conditions
Neurofibromatosis 2
Interventions
Penetrating auditory brainstem implant
Device
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
Los Angeles, California • Pasadena, California • Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 2 Interventional Results available

Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560

NCT04351373
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
Fluorescein Sodium, YELLOW560 filter
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Nov 2, 2026, 4:10 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Recovery of Visual Acuity in People With Vestibular Deficits

NCT00411216
View directory record Official record
Conditions
Vestibular Neuronitis, Vestibular Neuronitis, Bilateral, Vestibular Schwannoma
Interventions
Control exercises, gaze stabilization exercises
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2015 · Synced Nov 2, 2026, 4:10 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

StableEyes With Active Neurofeedback

NCT05622344
View directory record Official record
Conditions
Vestibular Disorder, Vestibular Schwannoma, Space Motion Sickness, Motion Sickness
Interventions
Traditional Therapy, SWAN
Behavioral · Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 2, 2026, 4:10 PM EST
Recruiting Not applicable Interventional

Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients With Vestibular Schwannomas

NCT05702749
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
Microsurgical resection of VS, Stereotactic radiosurgery, PREHAB
Procedure · Radiation · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Nov 2, 2026, 4:10 PM EST
Terminated Phase 2 Interventional

PTC299 for Treatment of Neurofibromatosis Type 2

NCT00911248
View directory record Official record
Conditions
Neurofibromatosis 2
Interventions
PTC299
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Nov 2, 2026, 4:10 PM EST
Terminated Phase 1 Interventional

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

NCT01552434
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
Interventions
Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid
Biological · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 2 Interventional Results available

Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System

NCT04743310
View directory record Official record
Conditions
Central Nervous System Tumor
Interventions
tozuleristide, Canvas imaging system, Surgical resection of tumor
Drug · Device · Procedure
Lead sponsor
John Yu
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 2, 2026, 4:10 PM EST
Active, not recruiting Not applicable Interventional

CI Following VS Removal or Labyrinthectomy

NCT03795675
View directory record Official record
Conditions
Vestibular Schwannoma, Meniere Disease
Interventions
Cochlear Implant
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 2, 2026, 4:10 PM EST
Completed No phase listed Observational

Subtotal Resection of Large Acoustic Neuromas With Possible Stereotactic Radiation Therapy

NCT01129687
View directory record Official record
Conditions
Neuroma, Acoustic
Interventions
Microsurgery, Stereotactic radiation therapy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
9
States / cities
Stanford, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Nov 2, 2026, 4:10 PM EST
Active, not recruiting No phase listed Observational

MElanoma Research Lymph Node Prediction Implementation National_001

NCT04759781
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
SkylineDx
Industry
Eligibility
18 Years and older
Enrollment
1,820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
9
States / cities
Tampa, Florida • Atlanta, Georgia • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Nov 2, 2026, 4:10 PM EST
Active, not recruiting Phase 2 Interventional

Study of Aspirin in Patients With Vestibular Schwannoma

NCT03079999
View directory record Official record
Conditions
Vestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
12 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
5
States / cities
Stanford, California • Miami, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 2, 2026, 4:10 PM EST
Terminated Not applicable Interventional

Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma

NCT05116878
View directory record Official record
Conditions
Vestibular Schwannoma
Interventions
Omega-3, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Nov 2, 2026, 4:10 PM EST
Recruiting No phase listed Observational

Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients

NCT05576103
View directory record Official record
Conditions
Primary Brain Tumor, Glioma, Meningioma, Schwannoma
Interventions
Not listed
Lead sponsor
Jona Hattangadi-Gluth
Other
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Nov 2, 2026, 4:10 PM EST
Terminated Early Phase 1 Interventional Results available

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

NCT02282917
View directory record Official record
Conditions
Vestibular Schwannoma, Meningioma, Acoustic Neuroma, Neurofibromatosis Type 2
Interventions
AR-42
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 2, 2026, 4:10 PM EST
Active, not recruiting Phase 2 Interventional

Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma

NCT01199978
View directory record Official record
Conditions
Vestibular Schwannoma, Acoustic Neuroma
Interventions
Fractionated proton radiation, Losartan
Radiation · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 2, 2026, 4:10 PM EST
Completed Phase 2 Interventional Results available

Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

NCT02129647
View directory record Official record
Conditions
Neurofibromatosis Type 2, Vestibular Schwannomas
Interventions
Axitinib
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Nov 2, 2026, 4:10 PM EST